Celltrion Applies for Phase 3 Clinical Trial Plan of Targeted Anticancer Drug Biosimilar
Celltrion announced on the 20th that it has submitted a clinical phase 3 trial plan for the Darzalex biosimilar (biopharmaceutical generic) 'CT-P44' to the Ministry of Food and Drug Safety.
Darzalex is a targeted anticancer drug that binds to a specific protein present on the surface of multiple myeloma cells to inhibit the growth of cancer cells.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Groups of 5 or More Now Restricted"... Unrelenting Running Craze Leaves Citizens and Police Exhausted
- Despite Warnings of "Do Not Enter, You May Not Make It Out Alive"... Foreign Tourist Stranded After Unauthorized Climb on Jeju Sanbangsan
- AI Bubble or Real Growth? All Eyes on NVIDIA's Q1 Earnings
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
In this clinical trial, Celltrion plans to demonstrate the similarity between Darzalex and CT-P44 in approximately 500 patients with refractory or relapsed multiple myeloma.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
